<<>>>
TitleUrlVersionPublisher
Hematocrit, Selected Blood Specimenshttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.508720220715Clinical Architecture
Secondary Erythrocytosis Disorder SNOMEDCThttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1920220315CMS DRLS Steward
BH Assessment for alcohol or other drugs CPThttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1257.1.182120170504CQAIMH Steward
COVID19 SNOMED Value Set for Pulmonary Regurgitationhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.623120220728Clinical Architecture
Acute Pulmonary Hemorrhagehttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.206820200910ACEP/AMA-PCPI Steward
Yellow Fever (Organism or Substance in Lab Results)http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.55920181031CSTE Steward
Pulse Exam of Foothttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.11.102020170504NCQA PHEMUR
Naloxone Opiate Antagonisthttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1200.16520230124Cliniwiz Steward
History of Malignancy SNOMEDhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.7620200620Meaningful Drug Interaction Alerts Steward
COVID19 ICD10CM Value Set for Chronic Liver Diseaseshttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.302620220713Clinical Architecture
Cancer Diagnosishttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.36620171106CancerLinQ Steward
Highly to Moderately Emetogenic Cancer Medicineshttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.36320161227Oncology Nursing Society Steward
Interventions Related to Medication Regimen, Discontinue Medicationhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.10720170801PharmacyHIT
Bronchiectasis Disorderhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.320220315CMS DRLS Steward
Tobacco Use (Safety)http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.137320211001HL7 Patient Care WG Steward
Malignant Neoplasm of bone of lower Limb, pelvis, sacrum, coccyxhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.7220180302Joint Commission
Moderate Respiratory Complications with LOShttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.17920230608Joint Commission
Chlordiazepoxide / Clidiniumhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.127620180310NCQA PHEMUR
Drugs [Non opioid] (Tests by Screen or Unspecified Method in Urine)http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.154820220118CSTE Steward
Neutrophil counthttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.103620140630Lantana EH Steward
BH Antidepressant Medicationhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1257.1.97220170825CQAIMH Steward
Diabetic Coma caused by Hypoglcemiahttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.48420210909HL7 Patient Care WG Steward
IUD Surveillancehttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.13820211013OPA Steward
Metastatic Melanomahttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.104220160311CAP Steward
N Stage pN1chttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.10420150820CancerLinQ Steward
Ischemic Stroke Otherhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.6020210220TJC EH Steward
t-PA ingredient specifichttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.620160331TJC EH Steward
Gavage Feeding I9http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.176620150430Lantana EH Steward
EGFR Mutation Positivehttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.1000.106920181201CAP Steward
Moderate Emetigenic Risk Chemotherapyhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.33320161222CancerLinQ Steward
<<>>>745746747748749<<>>>